Total Payments
$5,735
2024 Payments
$282.21
Companies
26
Transactions
269
Medicare Patients
11,203
Medicare Billing
$1.4M
Payment Breakdown by Category
Food & Beverage$5,635 (98.3%)
Education$100.05 (1.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,635 | 250 | 98.3% |
| Education | $100.05 | 19 | 1.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $1,316 | 46 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $548.91 | 28 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $388.10 | 19 | $0 (2020) |
| PFIZER INC. | $386.29 | 40 | $0 (2019) |
| Boston Scientific Corporation | $376.72 | 8 | $0 (2024) |
| Impulse Dynamics (USA) Inc. | $371.10 | 2 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $343.07 | 22 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $307.18 | 29 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $243.75 | 15 | $0 (2019) |
| Janssen Pharmaceuticals, Inc | $242.23 | 13 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $282.21 | 2 | Boston Scientific Corporation ($282.21) |
| 2023 | $449.48 | 2 | Ablacon, Inc. ($241.23) |
| 2022 | $162.85 | 1 | Impulse Dynamics (USA) Inc. ($162.85) |
| 2020 | $71.35 | 4 | SANOFI-AVENTIS U.S. LLC ($19.44) |
| 2019 | $1,106 | 44 | Amgen Inc. ($394.95) |
| 2018 | $1,744 | 100 | Amgen Inc. ($457.12) |
| 2017 | $1,920 | 116 | Amgen Inc. ($444.56) |
All Payment Transactions
269 individual payment records from CMS Open Payments — Page 10 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/22/2017 | Regeneron Healthcare Solutions, Inc. | PRALUENT ALIROCUMAB INJECTION (Biological) | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 05/16/2017 | Amgen Inc. | Corlanor (Drug), Repatha | Food and Beverage | In-kind items and services | $26.24 | General |
| Category: Cardiology | ||||||
| 05/15/2017 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $17.03 | General |
| Category: Hyperkalemia | ||||||
| 05/10/2017 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $23.41 | General |
| Category: Cardiovascular | ||||||
| 05/09/2017 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $22.86 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/25/2017 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $9.66 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/12/2017 | Amgen Inc. | Corlanor (Drug), Repatha | Food and Beverage | In-kind items and services | $26.93 | General |
| Category: Cardiology | ||||||
| 04/12/2017 | Amgen Inc. | — | Education | In-kind items and services | $10.00 | General |
| 04/11/2017 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: Hyperkalemia | ||||||
| 04/11/2017 | Sunovion Pharmaceuticals Inc. | BROVANA (Drug) | Food and Beverage | In-kind items and services | $7.63 | General |
| Category: RESPIRATORY | ||||||
| 04/06/2017 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $21.66 | General |
| Category: Cardiovascular | ||||||
| 03/27/2017 | Boehringer Ingelheim Pharmaceuticals, Inc. | PRADAXA (Drug), JARDIANCE, STIOLTO | Food and Beverage | In-kind items and services | $12.19 | General |
| Category: CARDIOVASCULAR | ||||||
| 03/24/2017 | Regeneron Healthcare Solutions, Inc. | PRALUENT ALIROCUMAB INJECTION (Biological) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 03/23/2017 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $19.09 | General |
| Category: CARDIOVASCULAR | ||||||
| 03/22/2017 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $18.53 | General |
| Category: Cardiovascular | ||||||
| 03/16/2017 | Amgen Inc. | Corlanor (Drug), Repatha | Food and Beverage | In-kind items and services | $20.03 | General |
| Category: Cardiology | ||||||
| 03/15/2017 | Actelion Pharmaceuticals US, Inc. | OPSUMIT MACITENTAN (Drug) | Food and Beverage | In-kind items and services | $19.64 | General |
| Category: CARDIOVASCULAR DISORDERS | ||||||
| 03/14/2017 | Amgen Inc. | Corlanor (Drug), Repatha | Food and Beverage | In-kind items and services | $25.75 | General |
| Category: Cardiology | ||||||
| 03/13/2017 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $12.29 | General |
| Category: Hyperkalemia | ||||||
| 03/10/2017 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/10/2017 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $3.76 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/09/2017 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $18.99 | General |
| Category: Cardiovascular | ||||||
| 03/09/2017 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $8.08 | General |
| Category: Cardiovascular | ||||||
| 03/08/2017 | Amgen Inc. | Corlanor (Drug), Repatha | Food and Beverage | In-kind items and services | $33.98 | General |
| Category: Cardiology | ||||||
| 03/07/2017 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $11.11 | General |
| Category: CARDIOVASCULAR | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 37 | 2,892 | 3,874 | $1.6M | $338,763 |
| 2022 | 38 | 2,975 | 3,992 | $1.6M | $371,167 |
| 2021 | 34 | 2,764 | 3,604 | $1.4M | $353,474 |
| 2020 | 40 | 2,572 | 3,913 | $1.3M | $319,480 |
Total Patients
11,203
Total Services
15,383
Medicare Billing
$1.4M
Procedure Codes
165
All Medicare Procedures & Services
165 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 390 | 622 | $304,158 | $96,972 | 31.9% |
| 78492 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress | Office | 2023 | 23 | 23 | $208,357 | $35,498 | 17.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 119 | 122 | $107,482 | $22,153 | 20.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 88 | 202 | $73,730 | $21,806 | 29.6% |
| 93314 | Interpretation and report of ultrasound of heart | Facility | 2023 | 240 | 248 | $110,360 | $19,480 | 17.7% |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 2023 | 23 | 46 | $39,790 | $19,201 | 48.3% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 85 | 86 | $100,706 | $16,123 | 16.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 58 | 58 | $40,426 | $11,116 | 27.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 153 | 155 | $38,440 | $9,257 | 24.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 75 | 81 | $29,484 | $8,262 | 28.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 41 | 47 | $33,088 | $7,243 | 21.9% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 49 | 86 | $26,041 | $6,758 | 25.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 287 | 501 | $41,583 | $6,620 | 15.9% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 31 | 31 | $33,542 | $6,424 | 19.2% |
| 75572 | Ct scan of heart structure with contrast | Facility | 2023 | 77 | 77 | $125,510 | $5,638 | 4.5% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 23 | 92 | $13,800 | $3,854 | 27.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 44 | 44 | $16,016 | $3,808 | 23.8% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Facility | 2023 | 224 | 230 | $15,870 | $3,701 | 23.3% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 12 | 55 | $5,940 | $3,238 | 54.5% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 55 | 141 | $17,766 | $2,997 | 16.9% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 49 | 120 | $18,000 | $2,794 | 15.5% |
| 75574 | Ct scan of blood vessels and grafts of heart with contrast | Facility | 2023 | 23 | 25 | $16,025 | $2,593 | 16.2% |
| 93281 | Programming of multiple lead pacemaker system | Office | 2023 | 14 | 27 | $9,531 | $2,310 | 24.2% |
| 32555 | Aspiration of fluid from chest cavity using imaging guidance | Facility | 2023 | 12 | 20 | $39,795 | $2,034 | 5.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 16 | 18 | $6,804 | $1,896 | 27.9% |
About Dr. Nellis Smith, M.D
Dr. Nellis Smith, M.D is a Clinical Cardiac Electrophysiology healthcare provider based in E Palo Alto, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1386678951.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nellis Smith, M.D has received a total of $5,735 in payments from pharmaceutical and medical device companies, with $282.21 received in 2024. These payments were reported across 269 transactions from 26 companies. The most common payment nature is "Food and Beverage" ($5,635).
As a Medicare-enrolled provider, Smith has provided services to 11,203 Medicare beneficiaries, totaling 15,383 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 165 distinct procedure/service records.
Ad
Practice Information
- Specialty Clinical Cardiac Electrophysiology
- Other Specialties Nuclear Cardiology, Cardiovascular Disease
- Location E Palo Alto, CA
- Active Since 07/10/2006
- Last Updated 05/28/2020
- Taxonomy Code 207RC0001X
- Entity Type Individual
- NPI Number 1386678951
Products in Payments
- ELIQUIS (Drug) $918.26
- Corlanor (Drug) $738.08
- Repatha (Biological) $567.86
- ENTRESTO (Drug) $343.07
- Rhythmia Mapping System (Device) $282.21
- PRALUENT (Drug) $275.96
- PRADAXA (Drug) $275.40
- XARELTO (Drug) $242.23
- OPTIMIZER (Device) $208.25
- BRILINTA (Drug) $205.60
- PRALUENT ALIROCUMAB INJECTION (Biological) $176.90
- Optimizer (Device) $162.85
- INJECTAFER (Drug) $130.73
- MULTAQ (Drug) $112.14
- WATCHMAN (Device) $94.51
- NORTHERA (Drug) $90.83
- Veltassa (Drug) $84.83
- PRALUENT (Biological) $66.85
- LifeVest (Device) $52.04
- UTIBRON (Drug) $37.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.